Mishaela Rubin, MD, MS, is a professor of medicine at Columbia University Irving Medical Center.

Mark Warren, MD, FACE is an endocrinologist and clinical associate professor at Campbell University School of Osteopathic Medicine.

Closing Thoughts on Hypoparathyroidism Management

In the final episode, ‘Closing Thoughts on Hypoparathyroidism Management,’ the panelists share their key takeaways from the series discussion on hypoparathyroidism.

Led by the moderator, Dr. Kohlmeier, the panelists, Dr. Rubin, Dr. Warren, and Dr. Al-Dallal, emphasize that PTH-based therapy marks a shift toward physiologic therapy beyond calcium supplementation. They also stress that chronic hypoparathyroidism is a lifelong, multisystem disease requiring individualized care and ongoing research. The panel highlight the need for clear communication with providers, vigilant safety practices, and a medical advocate when possible. Lastly, they describe the era as exciting, noting that meaningful treatment options, such as palopegteriparatide and others in development, will enable truly personalized management plans. Their insights underscore the importance of integrating emerging therapies with comprehensive monitoring to optimize patient outcomes significantly.

Thank you for watching this HCPLive Peer Exchange series on hypoparathyroidism. Please subscribe to our newsletter for information on upcoming video series.

Videos

Video Series

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Emerging Therapies in Hypoparathyroidism

In ‘Emerging Therapies in Hypoparathyroidism,’ our experts delve into three emerging therapies in chronic hypoparathyroidism.

Led by the moderator, Dr. Kohlmeier, the expert endocrinologists, Dr. Rubin, Dr. Warren, and Dr. Al-Dallal, examine the following critical questions:

What are your impressions of emerging therapies, such as eneboparatide (a PTH1R agonist), encaleret (a calcilytic agent), and MBX 2109 (PTH peptide prodrug) for their potential to manage chronic hypoparathyroidism?

The panel evaluates eneboparatide, a PTH1R agonist that closely mimics native parathyroid hormone signaling; MBX 2109, a PTH peptide prodrug engineered for sustained, physiologic PTH exposure; and encaleret, a calcilytic that modulates the calcium‑sensing receptor to enhance endogenous PTH release. Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Our next episode, ‘Closing Thoughts on Hypoparathyroidism Management,’ wraps up the series with the panelists’ final thoughts on the management of hypoparathyroidism.

In ‘Emerging Therapies in Hypoparathyroidism,’ our experts delve into three emerging therapies in chronic hypoparathyroidism.



Value of Medical Advocates for Patients and Educational Resources for Clinicians in Hypoparathyroidism

In this episode, ‘Value of Medical Advocates for Patients and Educational Resources for Clinicians in Hypoparathyroidism,’ the experts explore the importance of recommending medical advocates or medical alerts to patients as well as educational resources that are available for community providers to better manage hypoparathyroidism.

Led by the moderator, the panelists examine the following critical questions:

Do you recommend that your patients with chronic hypoparathyroidism have a medical advocate as well as a medical alert stating they are ‘Calcium Dependent’, and why is this important?

What other safety measures or educational tools do you recommend?

What educational resources and/or clinical tools would help community primary care providers and specialists better identify and manage chronic hypoparathyroidism?

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, ‘Emerging Therapies in Hypoparathyroidism,’ features the panelists advancing their conversation on hypoparathyroidism and focusing on several emerging therapies and their potential to manage chronic hypoparathyroidism.

In this episode, ‘Value of Medical Advocates for Patients and Educational Resources for Clinicians in Hypoparathyroidism,’ the experts explore the importance of recommending medical advocates or medical alerts to patients as well as educational resources that are available for community providers to better manage hypoparathyroidism.



Multidisciplinary Approaches to Hypoparathyroidism Management

This episode, titled ‘Multidisciplinary Approaches to Hypoparathyroidism Management,’ features expert endocrinologists discussing the role of multidisciplinary collaboration among endocrinologists, nephrologists, and primary care providers.

Do you feel multidisciplinary input can improve outcomes in patients with hypoparathyroidism, and if so, how might we encourage collaboration among endocrinologists, nephrologists, and primary care providers?

How do you encourage adherence and engagement over time in your patients with hypoparathyroidism given they require chronic monitoring and often have several providers?

In the next episode, ‘Value of Medical Advocates for Patients and Educational Resources for Clinicians in Hypoparathyroidism’, panelists will continue their discussion on hypoparathyroidism and highlight the importance of recommending medical advocates or medical alerts for patients as well as additional educational resources for clinicians to better identify and manage hypoparathyroidism.

This episode, titled ‘Multidisciplinary Approaches to Hypoparathyroidism Management,’ features expert endocrinologists discussing the role of multidisciplinary collaboration among endocrinologists, nephrologists, and primary care providers.



Safety and Titration Considerations and Quality of Life Impact of PTH-Based Therapy in Hypoparathyroidism

In ‘Safety and Titration Considerations and Quality of Life Impact of PTH-Based Therapy in Hypoparathyroidism,’ our panel delves into the potential titration challenges, safety considerations, and long-term monitoring of PTH-based therapy in patients with hypoparathyroidism. They also discuss the impact of PTH-based therapy on patient quality of life.

Led by the moderator, the expert endocrinologists examine the following critical questions:

What has been your experience initiating palopegteriparatide in your practice?

What challenges with titration have you encountered with your patients?

What side effects have patients described, and what safety measures and long-term monitoring do you recommend?

In what ways has palopegteriparatide impacted quality of life in your patients with chronic hypoparathyroidism?

Our next episode, ‘Multidisciplinary Approaches to Hypoparathyroidism Management,’ further explores hypoparathyroidism, highlighting the value of multidisciplinary collaboration, particularly in supporting patient adherence and engagement.

In this episode, ‘Addressing Bone Health in the Management of Hypoparathyroidism,’ the experts explore approaches to managing hypoparathyroidism in patients with osteoporosis.

Addressing Bone Health in the Management of Hypoparathyroidism

This episode, titled ‘Evaluating the Efficacy and Safety of Palopegteriparatide in Hypoparathyroidism from the PaTHway Trial,’ features panelists discussing the efficacy and safety data of palopegteriparatide in hypoparathyroidism from the phase 3 PaTHway trial as well as the limitations of the trial.

Evaluating the Efficacy and Safety of Palopegteriparatide in Hypoparathyroidism from the PaTHway Trial

In ‘Novel Approaches in Hypoparathyroidism Management,’ our experts delve into novel treatment options for patients who are inadequately controlled on conventional therapy and the mechanism of action of palopegteriparatide.

Novel Approaches in Hypoparathyroidism Management

In this episode, ‘Challenges of Conventional Therapy in Hypoparathyroidism,’ the expert endocrinologists explore conventional therapy for chronic hypoparathyroidism, symptom control, and the risk of complications. 


Challenges of Conventional Therapy in Hypoparathyroidism

In ‘Acute and Long-Term Complications of Hypoparathyroidism,’ our panel delves into the potential renal, neuromuscular, cognitive, and bone complications that impact patients.

Quality of Life Impact in Hypoparathyroidism

In ‘Acute and Long-Term Complications of Hypoparathyroidism,’ our panel delves into the potential renal, neuromuscular, cognitive, and bone complications that impact patients.

Led by the moderator, Dr. Kohlmeier, the expert panel, Dr. Rubin, Dr. Warren, and Dr. Al-Dallal, examines the following critical questions: 

1.	How is hypoparathyroidism diagnosed? 
2.	What are the key challenges in both diagnosing and monitoring patients with hypoparathyroidism? 

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, ‘Acute and Long-Term Complications of Hypoparathyroidism,’ features the panelists advancing their conversation on hypoparathyroidism and focusing on the potential renal, neuromuscular, cognitive, and bone complications that impact patients.

Acute and Long-Term Complications of Hypoparathyroidism

The panel concludes by discussing the future of ATTR-CM care. They highlight continued progress in disease-modifying therapies, with growing interest in determining how best to sequence or potentially combine treatments as evidence evolves. The group notes that as patients are diagnosed earlier, the goals of therapy may increasingly shift from slowing decline to preserving long-term function and quality of life.
They emphasize the importance of expanding awareness and education across specialties so that more patients are recognized before advanced cardiac dysfunction develops. Improving access to therapy remains an essential area of focus, as cost and insurance barriers continue to influence treatment decisions. The panel also anticipates advances in monitoring disease progression, including the use of biomarkers and imaging to better assess response over time.
Ultimately, the experts express optimism that ongoing research, broader recognition, and more refined care pathways will continue to improve outcomes for individuals living with ATTR-CM.


Future Directions in ATTR-CM

 In this episode, ‘Hypoparathyroidism Diagnosis and Challenges,’ the panelists explore how hypoparathyroidism is diagnosed as well as key diagnostic and monitoring challenges that clinicians face.

Led by the moderator, Dr. Kohlmeier, the expert panel, Dr. Rubin, Dr. Warren, and Dr. Al-Dallal, examines the following critical questions: 

1.	How is hypoparathyroidism diagnosed? 
2.	What are the key challenges in both diagnosing and monitoring patients with hypoparathyroidism? 

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, ‘Acute and Long-Term Complications of Hypoparathyroidism,’ features the panelists advancing their conversation on hypoparathyroidism and focusing on the potential renal, neuromuscular, cognitive, and bone complications that impact patients.

Hypoparathyroidism Diagnosis and Challenges

See how shared EHRs support collaborative care and review newer steroid-sparing topical therapies for pediatric atopic dermatitis and psoriasis.

EHR Collaboration and New Steroid-Sparing Topicals in Pediatric Dermatoses

Welcome back to another HCPLive Peer Exchange series. In this opening episode, panelists highlight the underlying causes of hypoparathyroidism and the impact of the loss of parathyroid hormone function by examining the following critical questions:

1.	What is chronic hypoparathyroidism, and how is it defined? 
2.	How does the loss of parathyroid hormone (PTH) function disrupt calcium and phosphate homeostasis in hypoparathyroidism? 
3.	What are the causes of chronic hypoparathyroidism, and is there any way to predict or prevent it? When might genetic testing be appropriate?

In the next episode, panelists will continue their discussion on hypoparathyroidism and highlight how it is diagnosed and the key challenges in the diagnosis and monitoring of patients with hypoparathyroidism.

Latest News

Closing Thoughts on Hypoparathyroidism Management

Emerging Therapies in Hypoparathyroidism

Value of Medical Advocates for Patients and Educational Resources for Clinicians in Hypoparathyroidism

Multidisciplinary Approaches to Hypoparathyroidism Management

Safety and Titration Considerations and Quality of Life Impact of PTH-Based Therapy in Hypoparathyroidism